Key Points

  • AbbVie plans a $1.4 billion pharmaceutical production facility spanning 185 acres in Durham, North Carolina
  • The project marks the drugmaker’s largest capital commitment to any individual location
  • Production will focus on injectable treatments targeting immunology, neuroscience and oncology patients
  • The facility will generate 734 full-time positions across four years, alongside 2,000+ construction roles
  • Development begins in 2026, targeting completion by late 2028

AbbVie revealed plans Wednesday to develop a $1.4 billion pharmaceutical production facility in Durham, North Carolina — representing the company’s most substantial investment in any single location to date.

The sprawling 185-acre complex will establish itself near Research Triangle Park, functioning as AbbVie’s primary U.S. hub for small volume parenteral (SVP) production. The facility will manufacture sterile injectable medications — including vials, syringes and prefilled cartridges — designed to treat patients across immunology, neuroscience and oncology therapeutic areas.

The Durham campus represents AbbVie’s inaugural significant presence in North Carolina.

Development will commence later this year, with full operations anticipated by late 2028. Initial construction phases encompass manufacturing facilities, laboratory spaces, warehousing, administrative offices and employee wellness centers.


ABBV Stock Card
AbbVie Inc., ABBV

AbbVie expects to bring aboard 734 permanent staff members over four years — including engineers, scientists, manufacturing operators and laboratory technicians. Construction activities will generate more than 2,000 jobs throughout the development period.

CEO Robert A. Michael stated the investment “strengthens our ability to support future medical breakthroughs while also creating new jobs and a long-term partnership with Durham and the State of North Carolina.”

Component of Massive $100 Billion Domestic Initiative

The Durham facility represents one element of a significantly larger strategy. AbbVie has committed approximately $100 billion toward U.S. research, development and manufacturing initiatives throughout the coming decade.

During the previous year, the pharmaceutical company allocated over $2.2 billion to domestic manufacturing expansions spanning North Carolina, Illinois, Arizona and Massachusetts.

This past February, AbbVie unveiled a $380 million commitment to construct two active pharmaceutical ingredient production facilities at its North Chicago, Illinois headquarters, concentrating on neuroscience and obesity therapeutics.

The Durham location builds upon this expansion trajectory.

Strategic Selection of North Carolina

AbbVie selected the Research Triangle Park region due to its highly trained workforce and capacity for long-term growth.

North Carolina Governor Josh Stein embraced the announcement, describing the state as “the premier location for biopharmaceutical companies to do business.”

Upon completion, the campus will distribute medications throughout domestic and global markets, serving as a primary center for AbbVie’s injectable pharmaceutical production across the United States.

AbbVie maintains approximately 29,000 employees throughout the U.S., with more than 6,000 working at domestic production facilities. This announcement brings the company’s total American job creation pledge over the past year beyond 1,300 new roles across four states.

The facility will incorporate artificial intelligence and cutting-edge manufacturing technologies throughout its operations — a feature AbbVie emphasized in its public statement.

This project establishes AbbVie’s inaugural manufacturing presence in North Carolina, with the company indicating the location has been planned to accommodate future pipeline expansion.